Novartis exec pushed out over Zolgensma data scandal denies wrongdoing

pharmafile | August 21, 2019 | News story | Research and Development AveXis, FDA, Novartis, Zolgensma, data scandal, pharma, sma 

Dr Brian Kaspar, the Novartis exec pushed out of AveXis over the Zolgensma data scandal, has said in a statement that he “categorically denies any wrongdoing.”

Speaking through a lawyer, Kaspar said he “stands proudly behind the safety and efficacy” of the $2.1 million gene therapy Zolgensma, and that he is “prepared to assert his rights and defend his conduct accordingly.”

The statement from law firm Heuston Hannigan, who previously represented Elon Musk, says: “Dr Brian Kaspar is a respected member of the scientific community with an impeccable record. He stands proudly behind the safety and efficacy of the drug that he and his team worked so hard to develop, and which remains an FDA-approved drug that is saving the lives of children who suffer from Spinal Muscular Atrophy.

Advertisement

“He has cooperated with Avexis’ internal investigation, and he categorically denies any wrongdoing. He is prepared to assert his rights and defend his conduct accordingly. Dr Kaspar continues to wish clinicians and the company continued success in the treatment of children with this deadly and devastating disease.”

Louis Goss

Related Content

Rare diseases – spinal muscular atrophy

Spinal muscular atrophy (SMA) is a rare disease characterised by voluntary muscle weakness that can …

MRM Health’s ulcerative colitis treatment receives FDA Investigational New Drug clearance

Microbial Resource Management (MRM) Health has announced that its lead programme, MH002, has received Investigational …

Complement Therapeutics’ geographic atrophy treatment receives FDA Fast Track designation

Complement Therapeutics has announced that CTx001, its gene therapy treatment for geographic atrophy (GA) secondary …

The Gateway to Local Adoption Series

Latest content